Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
8
×
national blog main
national top stories
new york blog main
new york top stories
novartis
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
8
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
cancer
cancer immunotherapy
deals
alzheimer's disease
biogen
gilead sciences
abbvie
eli lilly
fda
ipo
pfizer
What
roundup
bio
drug
acquisitions
ceo
new
biggest
companies
covid
daniel
gilead
including
ipo
medicines
nash
news
o’day
pharmaceutical
price
sciences
typically
according
activity
akcea
albert
alzheimer’s
announced
approval
approvals
bails
biogen
biogen’s
biopharmaceutical
biotech
bourla
brand
bridgebio
build
buy
capital
Language
unset
unknown
Current search:
novartis
×
biotech
×
startups
×
national
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More